checkAd

alytas therapeutics collaborates with spin-off from the German Diabetes Center

Xlife Sciences AG / Key word(s): Miscellaneous
alytas therapeutics collaborates with spin-off from the German Diabetes Center

28.11.2022 / 07:00 CET/CEST


Xlife Sciences’ (SIX: XLS) portfolio company alytas therapeutics (located in Jena, Germany) explores innovative, antibody-based therapeutic concepts for treatment of morbid obesity. The project is focused on the efficient elimination of hypertrophic adipocytes that are responsible for obesity-associated complications like cardiovascular disease, diabetes, or cancer. Therefore, antibody treatment will not only reduce body fat mass, but will also improve homeostasis of adipose tissue.

To conduct a deep functional in vitro characterization of recently identified antibodies, alytas therapeutics and CureDiab Metabolic Research have signed a research contract. As a spin-off from the German Diabetes Center in Duesseldorf, CureDiab is able to use the excellent lab infrastructure and expertise regarding adipose tissue metabolism.

Frank Plöger, Chief Scientific Officer of Xlife Sciences, says: “We are happy about the collaboration with CureDiab Metabolic Research for additional research and development of the innovative approach of alytas therapeutics for treatment of morbid obesity. It is our goal to contribute to treatment of affected patients by eliminating hypertrophic fat cells that play an essential role in the development of obesity-associated complications”.

Juergen Eckel, CEO of CureDiab, explains: “In this project, CureDiab will establish a model of hypertrophic adipocytes and explore the cellular changes of the respective antigens, with the final goal to identify binding and elimination of hypertrophic fat cells by specific antibodies. We highly appreciate the collaboration with alytas therapeutics and look forward to an exciting scientific project”.

 

Financial calendar

Annual Report 2022                                April 20, 2023

Ordinary AGM 2023                                June 22, 2023

Half-Year Report 2023                            September 21, 2023

Seite 1 von 3


Wertpapier



0 Kommentare
Nachrichtenquelle: EQS Group AG
 |  104   |   |   

Schreibe Deinen Kommentar

Disclaimer

alytas therapeutics collaborates with spin-off from the German Diabetes Center Xlife Sciences AG / Key word(s): Miscellaneous alytas therapeutics collaborates with spin-off from the German Diabetes Center 28.11.2022 / 07:00 CET/CEST Xlife Sciences’ (SIX: XLS) portfolio company alytas therapeutics (located in Jena, Germany) …

Nachrichten des Autors

952 Leser
800 Leser
616 Leser
472 Leser
468 Leser
1256 Leser
1224 Leser
1096 Leser
1056 Leser
976 Leser
2385 Leser
2343 Leser
2247 Leser
2237 Leser
2225 Leser